Compare Stocks

→ Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADRO Aduro Biotech		$10.93	$4.51 ▼ $20.20	$236.61M	0.4	162,237 shs	171,500 shs
ETON Eton Pharmaceuticals	$3.71 -1.1%	$3.78	$2.42 ▼ $5.81	$95.31M	1.19	51,230 shs	61,060 shs
SVRA Savara	$4.71 +0.6%	$4.91	$1.83 ▼ $5.70	$650.14M	0.73	1.08 million shs	630,574 shs

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADRO Aduro Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
ETON Eton Pharmaceuticals	-1.07%	+7.54%	+3.06%	-17.37%	-0.54%
SVRA Savara	+0.53%	+6.69%	-1.77%	-2.99%	+148.94%

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADRO Aduro Biotech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	1.4745 of 5 stars	3.5	5.0	0.0	0.0	0.0	0.8	0.0
SVRA Savara	3.0129 of 5 stars	3.5	5.0	0.0	0.0	2.3	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADRO Aduro Biotech	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	3.00	Buy	$10.00	169.54% Upside
SVRA Savara	3.00	Buy	$8.20	74.28% Upside

Current Analyst Ratings

Latest SVRA, ETON, and ADRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/18/2024	SVRA Savara	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
3/4/2024	SVRA Savara	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$7.00 ➝ $16.00
2/15/2024	SVRA Savara	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00

(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADRO Aduro Biotech	$17.26M	0.00	N/A	N/A	$4.07 per share	0.00
ETON Eton Pharmaceuticals	$31.64M	3.01	$0.00 per share	1,173.42	$0.60 per share	6.18
SVRA Savara	N/A	N/A	N/A	N/A	$1.04 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADRO Aduro Biotech	-$82.37M	-$5.15	N/A	N/A	N/A	-230.92%	-101.73%	-22.35%	N/A
ETON Eton Pharmaceuticals	-$940K	-$0.03	N/A	∞	N/A	-2.96%	-6.21%	-3.17%	5/9/2024 (Confirmed)
SVRA Savara	-$54.70M	-$0.33	N/A	N/A	N/A	N/A	-46.27%	-35.94%	5/20/2024 (Estimated)

Latest SVRA, ETON, and ADRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2024	N/A	ETON Eton Pharmaceuticals	-$0.02	N/A	+$0.02	N/A	N/A	N/A
3/14/2024	Q4 2023	ETON Eton Pharmaceuticals	-$0.04	-$0.09	-$0.05	-$0.09	$7.70 million	$7.31 million
3/7/2024	Q4 2023	SVRA Savara	-$0.11	-$0.09	+$0.02	-$0.09	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADRO Aduro Biotech	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADRO Aduro Biotech	N/A	8.91	8.91
ETON Eton Pharmaceuticals	N/A	1.65	1.60
SVRA Savara	0.19	15.66	15.66

Ownership

Institutional Ownership

Company	Institutional Ownership
ADRO Aduro Biotech	49.93%
ETON Eton Pharmaceuticals	27.86%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
ADRO Aduro Biotech	5.90%
ETON Eton Pharmaceuticals	13.16%
SVRA Savara	4.58%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADRO Aduro Biotech	152	16.21 million	N/A	Optionable
ETON Eton Pharmaceuticals	30	25.69 million	22.31 million	Optionable
SVRA Savara	N/A	138.18 million	131.85 million	Optionable

SVRA, ETON, and ADRO Headlines

Source	Headline
	Hemant Savara, former minister's son, is BJP's final pick in Maharashtra indiatoday.in - May 3 at 8:14 PM
	Optimistic Buy Rating on Savara Amid Anticipated IMPALA-2 Trial Success markets.businessinsider.com - May 3 at 8:14 PM
	Former state minister late Vishnu Savara's son Hemant is BJP's Palghar candidate msn.com - May 2 at 8:34 PM
	Savara (NASDAQ:SVRA) Stock Price Down 6.5% marketbeat.com - May 2 at 6:56 PM
	Savara's wife lip synchs a Luhya accent amusing Kenyans mpasho.co.ke - May 1 at 7:36 AM
	Savara Inc. (SVRA) Stock Price, News, Quote & History - Yahoo Finance finance.yahoo.com - April 25 at 8:08 PM
	Savara (NASDAQ:SVRA) Trading Down 6.6% marketbeat.com - April 24 at 6:51 PM
	Savara Inc (NASDAQ:SVRA) Shares Acquired by Jennison Associates LLC marketbeat.com - April 24 at 7:27 AM
	FYBR, BCRX and SABR are among after hour movers seekingalpha.com - April 20 at 1:53 AM
	Savara's (SVRA) Market Outperform Rating Reiterated at JMP Securities marketbeat.com - April 18 at 2:21 PM
	Savara (NASDAQ:SVRA) Trading Down 3.9% marketbeat.com - April 17 at 12:20 PM
	Savara (NASDAQ:SVRA) Sees Large Volume Increase marketbeat.com - April 15 at 1:54 PM
	Vanguard Group Inc. Buys 789,249 Shares of Savara Inc (NASDAQ:SVRA) marketbeat.com - April 14 at 4:16 AM
	Savara Calls Out Haters! ghettoradio.co.ke - April 13 at 12:23 PM
	Savara (NASDAQ:SVRA) Shares Up 3.6% marketbeat.com - April 11 at 1:47 PM
	Optimistic Buy Rating for Savara Based on Molgramostim’s Market Potential and Study Outcomes markets.businessinsider.com - April 11 at 8:38 AM
	Details of Savara’s Upcoming Projects ghettoradio.co.ke - March 27 at 5:19 AM
	Savara Announces New Employment Inducement Grant businesswire.com - March 22 at 4:05 PM
	Savara: Why Sauti Sol had to take a break from each other mpasho.co.ke - March 19 at 4:25 AM
	Savara Inc. Reports Increased Expenses, Anticipates Positive Data from IMPALA-2 Trial msn.com - March 13 at 1:33 PM
	FDA lifts partial hold on Nurix Phase 1 study for NX-2127 msn.com - March 11 at 6:57 PM
	Buy Rating Affirmed: Anticipating IMPALA-2 Trial Success and aPAP Treatment Breakthrough with Molgramostim markets.businessinsider.com - March 11 at 1:57 PM
	SVRA Jul 2024 7.500 call finance.yahoo.com - March 10 at 9:20 AM
	Optimistic Buy Rating for Savara on Molgramostim’s Market Potential and Strong Financials markets.businessinsider.com - March 8 at 9:43 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aduro Biotech

NASDAQ:ADRO

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

Eton Pharmaceuticals

NASDAQ:ETON

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Savara

NASDAQ:SVRA

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial